BACKGROUND: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. PATIENTS AND METHODS: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15-27.5) post-treatment. Age at follow-up was 39 years (range 27-59) and cumulative dose of doxorubicin was 360 mg/m(2) (range 225-550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. RESULTS: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. CONCLUSIONS: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.
BACKGROUND: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. PATIENTS AND METHODS: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15-27.5) post-treatment. Age at follow-up was 39 years (range 27-59) and cumulative dose of doxorubicin was 360 mg/m(2) (range 225-550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. RESULTS: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. CONCLUSIONS: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.
Authors: Cindy L Schwartz; Leonard H Wexler; Mark D Krailo; Lisa A Teot; Meenakshi Devidas; Laurel J Steinherz; Allen M Goorin; Mark C Gebhardt; John H Healey; Judith K Sato; Paul A Meyers; Holcombe E Grier; Mark L Bernstein; Steven E Lipshultz Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Frank Lohr; Felix Heggemann; Theano Papavassiliu; Mostafa El-Haddad; Oliver Tomé; Dietmar Dinter; Barbara Dobler; Uta Kraus-Tiefenbacher; Martin Borggrefe; Frederik Wenz Journal: Strahlenther Onkol Date: 2009-04-16 Impact factor: 3.621
Authors: C A J Brouwer; J A Gietema; M P van den Berg; M T E Bink-Boelkens; N J Elzenga; J Haaksma; W A Kamps; J M Vonk; A Postma Journal: J Cancer Surviv Date: 2007-09-27 Impact factor: 4.442
Authors: Cornelia A J Brouwer; Jourik A Gietema; Judith M Vonk; W J E Tissing; Hendrika M Boezen; Nynke Zwart; Aleida Postma Journal: Support Care Cancer Date: 2011-01-15 Impact factor: 3.603
Authors: R Altena; E C de Haas; J Nuver; C A J Brouwer; M P van den Berg; A J Smit; A Postma; D Th Sleijfer; J A Gietema Journal: Br J Cancer Date: 2009-05-19 Impact factor: 7.640